Cellectar Biosciences, Inc. reposted this
Outstanding ASTRO 2024! Thank you for the highly engaging and productive conference!
Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations. The company’s product pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), and proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. The company is currently enrolling in a global, pivotal Phase 2 Part B (CLOVER-WaM) expansion study in Waldenstrom’s macroglobulinemia (WM) patients who have received at least two prior lines of therapy, including Bruton tyrosine kinase inhibitor failed or suboptimal response patients. The WM study will enroll up to 50 patients to evaluate the efficacy and safety of CLR 131 for marketing approval. For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, Facebook and YouTube.
External link for Cellectar Biosciences, Inc.
100 Campus Dr
207
Florham Park, New Jersey 07932, US
Cellectar Biosciences, Inc. reposted this
Outstanding ASTRO 2024! Thank you for the highly engaging and productive conference!
We are energized to attend the 2024 ASTRO Annual Meeting in Washington DC. Learn more about Cellectar Biosciences and our PDC Platform at booth 2145! #WeWhoCurie #RadOnc
Cellectar Biosciences is showing support for #RareCancerDay through our research – Learn more about our pediatric #HighGradeGlioma clinical trial www.pediatrichggtrial.com. Learn more about other rare diseases from National Organization for Rare Disorders.
Our commitment to the Radiation Oncology community is rooted in collaboration and partnership. Cellectar is proud to be a gold sponsor for the American Society for Radiation Oncology (ASTRO) 2024 Annual Meeting. Learn more about our PDC platform at www.cellectar.com/moa.
Cellectar Biosciences is committed to solving challenges in pediatric cancer – learn about our #HighGradeGlioma trial now enrolling #PediatricCancerAwarenessMonth https://lnkd.in/g_QMN2CJ
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia https://bit.ly/3AHVJMU #IWWM12 #Waldenstroms #Presentations #Oncology #ClinicalResearch #BloodCancer
Exciting insights from Jim Caruso, CEO of Cellectar Biosciences, in his latest interview with Seeking Alpha, on the company's strategic advancements. Learn how Cellectar is leveraging its innovative phospholipid drug conjugate (PDC) technology to combat cancer. Read more about their groundbreaking research and upcoming milestones. https://bit.ly/46BQhqq #Biotech #CancerResearch #Leadership #CEOInsights #PharmaIndustry
Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update https://bit.ly/3WDAFhI #biopharma #radiopharmaceuticals #iopofosine #conferencecall #corporateupdate
UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 https://bit.ly/4dgLfSL #SecondQuarter #ConferenceCall
Cellectar’s dedication to finding new and better treatment options for Waldenstrom’s patients motivates us to give our all every day. Today, our CEO, Jim Caruso, additional company leadership, and key investigators will share a comprehensive overview of recent data from the CLOVER-WaM pivotal study during a conference call at 8:00 am EDT. For more information, visit: https://bit.ly/3XGT53f #KOLCall #ConferenceCall #CLOVERWaM #Radiotherapeutics #bloodcancer #waldenstroms #lymphoma #biopharma